Inhibitors of L1 and ADAM10 for the treatment of carcinomas

Details Inhibitors of L1 and ADAM10 for the treatment of carcinomas Inhibitors of L1 and ADAM10 for the treatment of carcinomas

2011-08-23

2011-08-23

Angell, Jon E (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S04400A

Reexamination Certificate

active

08003599

ABSTRACT:
Described is a pharmaceutical composition comprising a compound(s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound(s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described.

REFERENCES:
patent: 2003/0003449 (2003-01-01), Menzel et al.
patent: 2003/0211610 (2003-11-01), Condon et al.
patent: WO 02/04952 (2002-01-01), None
patent: WO 03/051825 (2003-06-01), None
patent: WO 03/106381 (2003-12-01), None
patent: WO 2004037198 (2004-05-01), None
patent: WO 2004/089294 (2004-10-01), None
Herskowitz (1987) Nature 329:219-222.
International Search Report, PCT/EP2005/008148, Jul. 27, 2005.
Hoefnagel, C. A. e al., “A comparison of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients”, European Journal of Nuclear Medicine, Berlin, Germany, vol. 28, No, 3, Mar. 2001, pp. 359-368.
Mechtersheimer, Sabine et al., “Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine biding to integrins”, Journal of Cell Biology, vol. 155, No. 4, Nov. 22, 2001, pp. 661-673.
Fogel, M. et al., “L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas”, Lancet The, Lancel Limited, London, GB, vol. 362, No. 9387, Sep. 13, 2003, pp. 869-875.
Hall, Ronelle J. and Erickson, Carol A., “ADAM10: an active metalloprotease expressed during avian epithelial morphogenesis”, Developmental Biology, Apr. 1, 2003, vol. 256, No. 1, pp. 146-159.
Lammich, Sven et al., “Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease”, Proc. Natl. Acad. Sci. USA, vol. 96, No. 7, pp. 3922-3927, Mar. 1999.
Riedle, Svenja, “Untersuchungen zur ADAM10-vermittelten Spaltung von L1 in Ovarialkarzinomzellen” Dissertation, published Aug. 19, 2004 (with English translation of Abstract), English translation only part considered.

Affiliated with

Also associated with

Rating

Inhibitors of L1 and ADAM10 for the treatment of carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of L1 and ADAM10 for the treatment of carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of L1 and ADAM10 for the treatment of carcinomas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675513